May 2015

Juno Therapeutics, Editas Medicine collaborate on cancer therapies

Friday, May 29, 2015

Juno Therapeutics, a Seattle-based biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and Editas Medicine, a Camrbidge, Mass.-based genome editing company, are collaborating on creating chimeric antigen receptor (CAR T) and high-affinity T cell receptor (TCR) therapies to treat cancer. The companies will pursue three research programs together utilizing Editas’ genome editing technologies, including CRISPR/Cas9, with Juno’s CAR and TCR technologies.

[Read More]

Amgen releases phase III AMG 416 data for secondary hyperparathyroidism in CKD

Friday, May 29, 2015

Amgen has released pooled data from two pivotal phase III, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis. Both studies met the primary endpoint, demonstrating that a greater proportion of patients in the AMG 416 groups achieved a greater than 30% reduction in parathyroid hormone (PTH) during the efficacy assessment phase compared with placebo.

[Read More]

DaVita Clinical Research expands nephrology clinical trial capabilities in Europe

Thursday, May 28, 2015

DaVita Clinical Research (DCR), a specialty CRO based in Minneapolis, has expanded its clinical trials capabilities in Europe. DCR now will be able to facilitate the conduct of late phase clinical trials in several medical centers outside of the U.S. Physician leaders from Germany, Poland and Portugal, with a combined 20 years of research experience, will collaborate with DCR to provide data and knowledge-based insights to its clients.

[Read More]